We compared therapeutic lipid target achievements among patients with diabetes or coronary heart disease (CHD) in Oman. A retrospective chart review of 94 patients was conducted at an outpatient clinic in Sultan Qaboos University Hospital, Muscat, Oman. The variables included low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and apolipoprotein B (apo B). The overall mean age of the cohort was 59 ± 12 years, 54% were male, 66% were diabetic, 48% hypertensive, 45% had CHD, 94% were on simvastatin, 4% were on fenofibrate, and 2% were on both simvastatin and fenofibrate. Lipid goal attainments of calculated LDL-C (<2.6 mmol/L), apo B (<0.9 g/L), and non-HDL-C (<3.36 mmol/L) were reached in 52%, 39%, and 53% of the patients, respectively. A significant proportion of high-risk patients treated with lipid-lowering agents reach LDL-C but not the apo B treatment targets, suggesting that the use of apo B target values should also be considered.
KearneyPMBlackwellLCollinsR. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371(9607):117–125.
2.
Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486–2496.
3.
American Diabetes Association. Management of dyslipidemia in adults with diabetes (position statement). Diabetes Care. 2003;26(suppl 1):S83–S86.
4.
SnidermanADSt-PierreACCantinBDagenaisGRDespresJPLamarcheB.Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. Am J Cardiol. 2003;91(10):1173–1177.
5.
WalldiusGJungnerIHolmeIAastveitAHKolarWSteinerE.High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001;358(9298):2026–2033.
6.
CuiYBlumenthalRSFlawsJA. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med. 2001;161(11):1413–1419.
7.
BittnerVHardisonRKelseySFWeinerBHJacobsAKSopkoG.Non high-density lipoprotein cholesterol levels predict five-year outcome in the bypass angioplasty revascularization investigation (BARI). Circulation. 2002;106(20):2537–2542.
8.
SnidermanADFurbergCDKeechA. Apoproteins versus lipids as indices of coronary risk and as targets for statin therapy: analysis of the evidence. Lancet. 2003;361(9359):777–780.
9.
BallantyneCMAndrewsTCHsiaJAKramerJHShearC.Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. Am J Cardiol. 2001;88(3):265–269.
10.
KasteleinJJvan der SteegWAHolmeI. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation. 2008;117(23):3002–3009.
11.
De GraafJCouturePSnidermanA.A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinaemias. Nat Clin Pract Endocrinol Metab. 2008;4(11):608–618.
12.
BrunzellJDDavidsonMFurbergCD. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008;31(4):811–822.
13.
LDL Cholesterol Method Certification protocol for Manufacturers. National Reference System for Cholesterol. Cholesterol Reference Method Laboratory Network; October1997.
14.
FriedewladWTLevyRIFredricksonDS.Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499–502.
GottoAMJrWhitneyESteinEA. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. 2000;101(5):477–484.
17.
SimesRJMarshnerICHuntD. Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?Circulation. 2002;105(10):1162–1169.
18.
van LennepJEWesterveldHTvan LennepHWZwindermanAHErkelensDWvan der WallEE.Apolipoprotein concentrations during treatment and recurrent coronary artery disease events. Arterioscler Thromb Vasc Biol. 2000;20(11):2408–2413.
19.
IdrisITateHAhmadAMcCormackT.Concordance between plasma apolipoprotein B levels and cholesterol indices among patients receiving statins and nonstatin treatment: post-hoc analyses from the UK in practice study. J Clin Lipid. 2011;5(4):316–323.
20.
LevinsonSSBlevinsRDSmithMPRubinfireMMaciejkoJJ. The relationship between apolipoprotein B-100 and low-density lipoprotein cholesterol after treatment with an HMG CoA reductase inhibitor. Am J Clin Pathol. 1989;92(4):479–483.
21.
LuWResnickHEJablonskiKA. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study. Diabetes Care. 2003;26(3):16–23.
22.
Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–3421.
23.
McQueenMJHawkenSWangX. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case–control study. Lancet. 2008;372(9634):224–233.
24.
IllingworthDRSteinEAMitchelYB. Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. Arch Intern Med. 1994;154(14):1586–1595.
25.
IdrisIAl-UbaidiF.Discordance between non-HDL cholesterol and LDL cholesterol levels in patients with diabetes without previous cardiovascular events. Diabetes Metab. 2010;36(4):299–304.
26.
KathiresanSOtvosJDSullivanLM. Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation. 2006;113(1):20–29.
27.
GarveyWTKwonSZhengD. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes. 2003;52(2):453–462.
28.
WilliamsKSnidermanADSattarN. Comparison of the associations of apolipoprotein b and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2003;108(19):2312–2316.
29.
SnidermanAD.Non-HDL cholesterol versus apolipoprotein B in diabetic dyslipoproteinemia. Alternatives and surrogates versus the real thing. Diabetes Care. 2003;26(7):2207–2208.
30.
SnidermanAD. Apolipoprotein B versus non-high-density lipoprotein cholesterol. And the winner is…Circulation. 2005;112(22):3366–3367.
31.
GandaOPJumesCGAbrahamsonMJ. Quantification of concordance and discordance between apolipoprotein-B and the currently recommended non-HDL-cholesterol goals for cardiovascular risk assessment in patients with diabetes and hypertriglyceridemia. Diabetes Res Clin Pract. 2012;97(1):51–56.
32.
WägnerAMPérezAZapicoEOrdóñez-LlanosJ. Non-HDL cholesterol and apolipoprotein B in the dyslipidemic classification of type 2 diabetic patients. Diabetes Care. 2003;26(7):2048–2051.
33.
CanMAcikgozSMunganG. Is direct method of low density lipoprotein cholesterol measurement appropriate for targeting lipid lowering therapy?Int J Cardiol. 2009;142(1):105–107.
34.
Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomized trials. Lancet. 2010;376(9753):1670–1681.
